STONY BROOK, NY -- (Marketwired) -- 10/01/15

Dr. James A. Hayward, president and CEO of Applied DNA Sciences, Inc. (NASDAQ: APDN), a provider of DNA-based anti-counterfeiting technology, product genotyping and product authentication solutions, was interviewed by TheStreet.com on Monday, September 28.

During the interview, Dr. Hayward spoke with host Gregg Greenberg about the Company's DNA marking solutions and how they can be used to deter theft and prevent incursion of counterfeit product into a legitimate supply chain. In addition to discussing the use of the Company's DNA marking for cash-in-transit and its track record of success in securing convictions for theft in the UK, Dr. Hayward spotlighted the Company's recent acquisition of the assets of Vandalia Research and its partnership with Creative Labels. He also cited the Company's positive topline growth over the past three quarters and its potential for future growth in the market.

To view the interview in its entirety, please visit the following link: http://archive.courier-journal.com/VideoNetwork/4516001886001/Applied-DNA-Sciences-Making-Mark-in-Tough-Biotech-Market

The video link above is provided for informational purposes only. Applied DNA Sciences, Inc. is not responsible for the content of the linked video and article.

About Applied DNA Sciences
We make life real and safe by providing botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the platform ingredient that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of uncopyable products such as DNAnet®, our anti-theft product, SigNature® T and fiberTyping®, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.

Applied DNA Sciences common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward Looking Statements
The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 15, 2014, as amended on March 6, 2015, and our subsequent quarterly reports on Form 10-Q filed on February 9, 2015, May 11, 2015 and August 10, 2015, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact:
Debbie Bailey
631-240-8817
Email contact

media contact:
Susan Forman
Dian Griesel Int'l.
212-825-3210
Email contact

web: Email contact
twitter: @APDN